메뉴 건너뛰기




Volumn 28, Issue 2, 2017, Pages 377-385

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature

Author keywords

Anti CTLA 4; Anti PD 1; Immune related adverse event; Melanoma; Neurological toxicity

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 85019549399     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw558     Document Type: Article
Times cited : (213)

References (17)
  • 1
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl JMed 2015; 372(4): 320-330.
    • (2015) N Engl JMed , vol.372 , Issue.4 , pp. 320-330
    • Robert, C.1    Long, G.V.2    Brady, B.3
  • 2
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
    • Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-384.
    • (2015) Lancet Oncol , vol.16 , Issue.4 , pp. 375-384
    • Weber, J.S.1    D'Angelo, S.P.2    Minor, D.3
  • 3
    • 84938205998 scopus 로고    scopus 로고
    • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
    • Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8): 908-918.
    • (2015) Lancet Oncol , vol.16 , Issue.8 , pp. 908-918
    • Ribas, A.1    Puzanov, I.2    Dummer, R.3
  • 4
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526.
    • (2011) N Engl J Med , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 5
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
    • (2015) N Engl J Med , vol.373 , Issue.1 , pp. 23-34
    • Larkin, J.1    Chiarion-Sileni, V.2    Gonzalez, R.3
  • 6
    • 84933678156 scopus 로고    scopus 로고
    • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
    • Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16(5): 522-530.
    • (2015) Lancet Oncol , vol.16 , Issue.5 , pp. 522-530
    • Eggermont, A.M.M.1    Chiarion-Sileni, V.2    Grob, J.-J.3
  • 7
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-2532.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2521-2532
    • Robert, C.1    Schachter, J.2    Long, G.V.3
  • 8
    • 84872339660 scopus 로고    scopus 로고
    • The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
    • Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8(1): e53745.
    • (2013) PLoS One , vol.8 , Issue.1
    • Voskens, C.J.1    Goldinger, S.M.2    Loquai, C.3
  • 9
    • 84964389238 scopus 로고    scopus 로고
    • Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
    • Zimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-225.
    • (2016) Eur J Cancer , vol.60 , pp. 210-225
    • Zimmer, L.1    Goldinger, S.M.2    Hofmann, L.3
  • 10
    • 84976585919 scopus 로고    scopus 로고
    • (1 July 2016, date last accessed)
    • Yervoy-Summary of Product Characteristics. http://www.medicines. org.uk/emc/medicine/24779 (1 July 2016, date last accessed).
    • Yervoy-Summary of Product Characteristics
  • 11
    • 77952118055 scopus 로고    scopus 로고
    • (1 July 2016, date last accessed)
    • Opdivo-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30476 (1 July 2016, date last accessed).
    • Opdivo-Summary of Product Characteristics
  • 12
    • 77952118055 scopus 로고    scopus 로고
    • (1 July 2016, date last accessed)
    • Keytruda-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30602 (1 July 2016, date last accessed).
    • Keytruda-Summary of Product Characteristics
  • 15
    • 84883053806 scopus 로고    scopus 로고
    • Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
    • Manousakis G, Koch J, Sommerville RB et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013; 48(3): 440-444.
    • (2013) Muscle Nerve , vol.48 , Issue.3 , pp. 440-444
    • Manousakis, G.1    Koch, J.2    Sommerville, R.B.3
  • 16
    • 84873821509 scopus 로고    scopus 로고
    • PD-1 is a novel regulator of human B-cell activation
    • Thibult M-L, Mamessier E, Gertner-Dardenne J et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013; 25(2): 129-137.
    • (2013) Int Immunol , vol.25 , Issue.2 , pp. 129-137
    • Thibult, M.-L.1    Mamessier, E.2    Gertner-Dardenne, J.3
  • 17
    • 84918507355 scopus 로고    scopus 로고
    • The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells
    • Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014; 41(6): 1026-1039.
    • (2014) Immunity , vol.41 , Issue.6 , pp. 1026-1039
    • Sage, P.T.1    Paterson, A.M.2    Lovitch, S.B.3    Sharpe, A.H.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.